Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joe Proctor

Internal Medicine New Iberia, LA Medical Doctor

NPI 1205129582 CMS profile 1309113

520 N Lewis St Ste 204, New Iberia, LA 70563

Open in the dashboard

General payments

$3,030

187 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joe Proctor of New Iberia, LA is reported in the CMS Open Payments database as having received $3,030 across 187 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $567 35
2024 General $626 32
2023 General $446 28
2022 General $231 12
2021 General $480 34
2020 General $241 15
2019 General $439 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joe Proctor
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Joe Proctor were reported at $567. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Joe Proctor Internal Medicine median Middle half National median
2019 $439 $159 $48–$570 $163
2020 $241 $119 $33–$402 $114
2021 $480 $135 $37–$521 $132
2022 $231 $141 $42–$496 $149
2023 $446 $149 $45–$519 $160
2024 $626 $154 $47–$537 $164
2025 $567 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $362 24 payments
  2. Lilly USA, LLC $348 23 payments
  3. Amgen Inc. $331 23 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $272 19 payments
  5. Janssen Pharmaceuticals, Inc $151 11 payments
  6. AbbVie, Inc. $144 8 payments
  7. Reapplix Inc. $121 1 payment
  8. Novo Nordisk Inc $114 7 payments
  9. Novartis Pharmaceuticals Corporation $113 6 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $113 7 payments
  11. Other $961 58 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,028 186 payments
  2. Education $1 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $288 19 payments
  2. Otezla $208 15 payments
  3. VYVANSE $171 12 payments
  4. Repatha $166 10 payments
  5. XARELTO $151 11 payments
  6. MOUNJARO $134 8 payments
  7. 3C Patch Kit - Box $121 1 payment
  8. SPIRIVA RESPIMAT $119 7 payments
  9. VRAYLAR $118 7 payments
  10. JARDIANCE $107 7 payments
  11. Other $2,317 145 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 173 drugs

Part D claims

12,794

Median for Family Practice: 1,826

Drug cost

$1,410,178

Median for Family Practice: $120,094

Branded share of claims

25.6%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 188 $209,411
Jardiance Empagliflozin Brand 227 $152,546
Eliquis Apixaban Brand 161 $128,529
Farxiga Dapagliflozin Propanediol Brand 135 $98,355
Trulicity Dulaglutide Brand 66 $68,525
Januvia Sitagliptin Phosphate Brand 73 $62,459
Ozempic Semaglutide Brand 53 $59,688
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 90 $59,214
Entresto Sacubitril/Valsartan Brand 61 $45,841
Linzess Linaclotide Brand 63 $37,073

The 10 drugs with the highest cost, of 173 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$104,809

Of which drugs: $10,755

Medicare patients

288

Average age 74

Services billed

1,823

153 women, 135 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 40%
Arthritis 38%
Diabetes 31%
Chronic kidney disease 24%
Depression 23%
Heart failure 20%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 93 95 $7,723
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 19 42 $184

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $65
$65 188 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $58
$58 135 —
IBSRELA
  • Ardelyx, Inc. $40
$40 — —
Repatha
  • Amgen Inc. $39
$39 48 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $29
$29 21 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

187 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record